ArticleInternational journal of ophthalmology2018
The diluted atropine for inhibition of myopia progression in Korean children.
Article in International journal of ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The effectiveness of atropine 0.05% eye drops versus placebo on controlling myopia progression among school children in randomized controlled trials: a systematic review and meta analysis.BMC ophthalmology · 2026Pooled it
- Varying Dose of Atropine in Slowing Myopia Progression in Children Over Different Follow-Up Periods by Meta-Analysis.Frontiers in medicine · 2021Pooled it
- Efficacy and safety of atropine to control myopia progression: a systematic review and meta-analysis.BMC ophthalmology · 2020Pooled it
- Changes in accommodation and vergence parameters with topical use of 0.025% and 0.05% atropine in myopes aged between 7 and 17 years.Eye (London, England) · 2025Trial
- Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial.Scientific reports · 2021Trial
- Myopia Management Consensus Statement in South Korean Children 2025 by the Korean Myopia Society for the Korean Association for Pediatric Ophthalmology and Strabismus.Korean journal of ophthalmology : KJO · 2026Review
- Recent Practice Patterns in Pediatric Myopia Control: Insights from a Nationwide Survey of South Korean Pediatric Ophthalmologists.Korean journal of ophthalmology : KJO · 2026Article
- Efficacy and safety of orthokeratology sequentially combined with escalating atropine concentrations for myopia control in children.Scientific reports · 2025Article
- Effectiveness of 0.01% atropine and orthokeratology for incipient myopia: a 1-year retrospective study.BMC ophthalmology · 2025Article
- Therapeutic Effect of Topical 0.125% Atropine in South Korean Myopic Children: A Real-World Experience.Korean journal of ophthalmology : KJO · 2025Article
- The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia.Ophthalmology and therapy · 2025Article
- Effectiveness of a split-dose, twice-daily low-dose atropine monocular treatment in children with anisometropia: a retrospective study.International ophthalmology · 2025Article
- Article
- Effectiveness of various atropine concentrations in myopia control for Asian children: a network meta-analysis.Frontiers in pharmacology · 2024Article
- Effect of 0.02% and 0.01% atropine on ocular biometrics: A two-year clinical trial.Frontiers in pediatrics · 2023Article
- Effects of low-concentration atropine eye drops on the optical quality of the eyes in myopic children.Indian journal of ophthalmology · 2022Article
- Characteristics of responders to atropine 0.01% as treatment in Asian myopic children.Scientific reports · 2022Observational
- Classification-Based Approaches to Myopia Control in a Taiwanese Cohort.Frontiers in medicine · 2022Article
- Risk factors for rapid axial length elongation with low concentration atropine for myopia control.Scientific reports · 2021Article
- The Effect of Long-Term Low-Dose Atropine on Refractive Progression in Myopic Australian School Children.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of three different concentrations of diluted atropine for the control of myopia in Korean children, and to assess the risk factors associated with rapid myopia progression.
methodsA total of 285 children, with refractive errors within the range of -6 diopters (D) between 5 and 14 years of age were included. After using 0.01%, or 0.025%, or 0.05% atropine, for about 1y, changes in refraction, axial lengths and frequency of adverse events were analyzed. Logistic regression analyses were performed to evaluate the risk factors associated with rapid myopia progression.
resultsThe changes in the mean spherical equivalent values were -0.134 D/mo in the before atropine group, -0.070 D/mo in the 0.01% atropine group, -0.047 D/mo in the 0.025% atropine group, and -0.019 D/mo in the 0.05% atropine group, with significant differences between the groups (
conclusionTreatment with 0.01%, 0.025% and 0.05% atropine solution inhibits myopia progression in Korean children in a dose-dependent manner. Children with highly myopic parents preferentially shows a rapid myopia progression rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.